Pi Therapeutics is developing a small molecule drug with an unique MoA targeting protein degradation.
Pi Therapeutics is developing small molecule compounds that inhibit protein degradation through a novel mechanism of action.
Their small molecule targets protein degradation pathways, without directly inhibiting the proteasome of the ubiquitin proteasome system.
The global Multiple Myeloma market is expected to exceed $30B by 2024
Ori Kalid, PhD – CEO
Dr. Kalid received his PhD from Tel Aviv University. He has over 16 years of industry experience in drug discovery and translational research, and previously served as head of Discovery and director of Translational Research at Karyopharm Therapeutics and director of Computer-Aided Drug Discovery at Epix Pharmaceuticals.